Zurück zur Übersicht
| Cancer research. 2021 Oct 8. pii: 0008-5472.CAN-21-1499. doi: 10.1158/0008-5472.CAN-21-1499 |
| Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients. |
| Woitek R1, McLean MA2, Ursprung S3, Rueda OM4, Manzano Garcia R5, Locke MJ6, Beer L7, Baxter G8, Rundo L9, Provenzano E10, Kaggie JD11, Patterson A12, Frary A13, Field-Rayner J14, Papalouka V15, Kane J16, Benjamin AJV17, Gill AB18, Priest AN19, Lewis DY20, Russell R21, Grimmer A22, White B23, Latimer EC24, Patterson I25, Schiller A26, Carmo B27, Slough R28, Lanz T29, Wason J30, Schulte RF31, Chin SF32, Graves MJ33, Gilbert FJ34, Abraham J35, Caldas C36, Brindle KM37, Sala E38, Gallagher FA39 |
 Author information
|
|
Abstract Hyperpolarized 13C-magnetic resonance imaging (MRI) is an emerging tool for probing tissue metabolism by measuring 13C-label exchange between intravenously injected hyperpolarized [1-13C]pyruvate and endogenous tissue lactate. Here we demonstrate that hyperpolarized 13C-MRI can be used to detect early response to neoadjuvant therapy in breast cancer. Seven patients underwent multiparametric 1H-MRI and hyperpolarized 13C-MRI before and 7-11 days after commencing treatment. An increase in the lactate-to-pyruvate ratio of ~20% identified three patients who, following 5-6 cycles of treatment, showed pathological complete response. This ratio correlated with gene expression of the pyruvate transporter MCT1, and lactate dehydrogenase A (LDHA), the enzyme catalyzing label exchange between pyruvate and lactate. Analysis of ~2000 breast tumors showed that overexpression of LDHA and the hypoxia marker CAIX were associated with reduced relapse-free and overall survival. Hyperpolarized 13C-MRI represents a promising method for monitoring very early treatment response in breast cancer and has demonstrated prognostic potential. |
|
Publikations ID: 34625424 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
